c01b5135.b754.4c57.a81d.68a951803fab
— · cohortMD1
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortMD1
- subtype
- cohortMD1
- age_years
- 77
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.500
- G2M_CHECKPOINT+0.390
- SPERMATOGENESIS+0.190
- DNA_REPAIR+0.160
- MITOTIC_SPINDLE+0.120
- MYC_TARGETS_V2+0.040
- KRAS_SIGNALING_DN+0.020
- MYOGENESIS-0.130
- CHOLESTEROL_HOMEOSTASIS-0.150
- ESTROGEN_RESPONSE_EARLY-0.150
Top 10 suppressed
- ALLOGRAFT_REJECTION-0.560
- INFLAMMATORY_RESPONSE-0.470
- ANGIOGENESIS-0.460
- IL2_STAT5_SIGNALING-0.460
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.440
- IL6_JAK_STAT3_SIGNALING-0.440
- PROTEIN_SECRETION-0.440
- OXIDATIVE_PHOSPHORYLATION-0.430
- UNFOLDED_PROTEIN_RESPONSE-0.430
- ADIPOGENESIS-0.420
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
5 twins match this tumor's tissue · 5 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SAMN03290905 | — | — | 0.942 |
| 2 | C3N-03886 | — | cohortMD1 | 0.922 |
| 3 | BS_4W68NV3M | medulloblastoma | — | 0.919 |
| 4 | SRR8518343 | — | E | 0.918 |
| 5 | BS_VAAHBH60 | EPN | Supratentorial EPN | 0.917 |
| 6 | BS_3NWQXPQV | medulloblastoma | — | 0.917 |
| 7 | BS_VAAHBH60 | Supratentorial Ependymoma | — | 0.911 |
| 8 | MBCProject_0381_T1_RNA | — | B | 0.910 |
| 9 | BS_NZ71XCG3 | medulloblastoma | — | 0.905 |
| 10 | TCGA-50-5946-01A-11R-1755-07 | — | cohortA1 | 0.903 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 7 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.500 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.390 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.190 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.160 | Idelalisib | — uncovered |
| MITOTIC_SPINDLE | 0.120 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.040 | Idelalisib | — uncovered |
| KRAS_SIGNALING_DN | 0.020 | Remibrutinib | — uncovered |